1. Home
  2. SLQT vs ALLO Comparison

SLQT vs ALLO Comparison

Compare SLQT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SelectQuote Inc.

SLQT

SelectQuote Inc.

HOLD

Current Price

$1.67

Market Cap

248.1M

Sector

Finance

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLQT
ALLO
Founded
1999
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
248.1M
252.9M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
SLQT
ALLO
Price
$1.67
$1.65
Analyst Decision
Hold
Strong Buy
Analyst Count
2
12
Target Price
$3.88
$8.27
AVG Volume (30 Days)
1.2M
4.1M
Earning Date
02-09-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,563,142,000.00
N/A
Revenue This Year
$13.00
N/A
Revenue Next Year
$7.65
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
13.16
N/A
52 Week Low
$1.33
$0.86
52 Week High
$6.86
$3.78

Technical Indicators

Market Signals
Indicator
SLQT
ALLO
Relative Strength Index (RSI) 61.94 60.75
Support Level $1.34 $1.62
Resistance Level $1.76 $1.88
Average True Range (ATR) 0.09 0.11
MACD 0.04 0.02
Stochastic Oscillator 80.95 59.83

Price Performance

Historical Comparison
SLQT
ALLO

About SLQT SelectQuote Inc.

SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: